merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safer, regulated option compared to compounded drugs</answer>
<question_number>2</question_number>
<answer>Direct-to-consumer sales through LillyDirect bypassing telehealth providers</answer>
<question_number>3</question_number>
<answer>Lack of safety, quality, and effectiveness control in compounded drugs</answer>
<question_number>4</question_number>
<answer>To attract customers away from compounded alternatives and regain market share</answer>
<question_number>5</question_number>
<answer>Removing tirzepatide from the FDA's shortage list would prevent compounding pharmacies from producing it</answer>
<question_number>6</question_number>
<answer>Direct sales to consumers with transparent pricing by eliminating third-party intermediaries</answer>
<question_number>7</question_number>
<answer>Increased use of weight-loss medications by Medicare beneficiaries who must self-pay</answer>
<question_number>8</question_number>
<answer>Patients may view Lilly's vials as safer than compounded tirzepatide</answer>
<question_number>9</question_number>
<answer>Being listed as "in shortage" by the FDA</answer>
<question_number>10</question_number>
<answer>Lowering prices to reclaim market share</answer>